Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials
- 11 April 2011
- journal article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 21 (6) , 572-578
Abstract
Efficacy, safety, and pharmacokinetics results from 4 studies—3 open-label (OL) and 1 randomized double-blind (DB)—have provided data for approval of etanercept for treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory juvenile idiopathic arthritis (JIA) in Japan. Results from the 3 shorter-term (2 OL and 1 DB) studies are reported here. Subjects (4–17 years) enrolled in the OL studies had active JIA, i.e. ≥ 5 swollen joints and ≥ 3 joints with limitation of motion and pain or tenderness. Subjects enrolled in the primary OL study received etanercept 0.4 mg/kg subcutaneously twice weekly; in the lower-dose OL study subjects received etanercept 0.2 mg/kg. Subjects in the primary OL study who completed ≥ 48 weeks could continue into a 12-week DB dose-down extension study in which subjects received etanercept 0.4 or 0.2 mg/kg twice weekly. The primary endpoint in all 3 studies, i.e. 30% improvement in the American College of Rheumatology criteria for JIA (ACR Pedi 30) at 12 weeks, was achieved by ≥ 80% of subjects by week 2 and sustained to week 12. Common adverse events reported were injection site reactions, nasopharyngitis, and gastroenteritis. These results provide further evidence that etanercept is effective therapy for DMARD-refractory polyarticular JIA patients.Keywords
This publication has 11 references indexed in Scilit:
- Long‐term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritisArthritis & Rheumatism, 2009
- Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national registerAnnals of the Rheumatic Diseases, 2009
- Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritisArthritis & Rheumatism, 2008
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IArthritis & Rheumatism, 2007
- Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical studyAnnals of the Rheumatic Diseases, 2007
- Long‐term safety and efficacy of etanercept in children with polyarticular‐course juvenile rheumatoid arthritisArthritis & Rheumatism, 2006
- Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label studyAnnals of the Rheumatic Diseases, 2003
- Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trialArthritis & Rheumatism, 2003
- Etanercept in Children with Polyarticular Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Preliminary definition of improvement in juvenile arthritisArthritis & Rheumatism, 1997